Nechemia Peres - Teva Pharma Independent Director
| TEVA Stock | USD 16.57 0.02 0.12% |
Director
Mr. Nechemia Jacob Peres is Independent Director of the Company. Mr. Peres joined the Board of Directors in July 2017. Mr. Peres serves as the managing general partner and cofounder of Pitango VC, Israels largest VC group that invests across technology sectors from IT to healthcare, with over 220 portfolio companies, since its inception in 1996. Mr. Peres serves on the board of directors of numerous Pitango portfolio companies. Mr. Peres is also the founder of Mofet Israel Technology Fund, one of Israels first VC funds, since its inception in 1992 since 2017.
| Age | 61 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 124 Dvora HaNevi?a Street, Tel Aviv, Israel, 6944020 |
| Phone | 972 3 914 8213 |
| Web | https://www.tevapharm.com |
Teva Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0556 % which means that it generated a profit of $0.0556 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1752) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.01. At present, Teva Pharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 3.42, whereas Total Assets are forecasted to decline to about 26.4 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Willie Reed | Zoetis Inc | 65 | |
| Michael Barber | Catalent | 60 | |
| Amy Wechsler | Bausch Health Companies | 50 | |
| Koji Hatsukawa | Takeda Pharmaceutical Co | 68 | |
| Joshua Smiley | Elanco Animal Health | 50 | |
| Madhavan Balachandran | Catalent | 69 | |
| Kapila Anand | Elanco Animal Health | 67 | |
| Paul Bisaro | Zoetis Inc | 59 | |
| Margaret Atkins | Aurora Cannabis | 63 | |
| Carl McMillian | Elanco Animal Health | 53 | |
| William Doyle | Elanco Animal Health | 58 | |
| Robert Power | Bausch Health Companies | 63 | |
| Rosemary Crane | Catalent | 60 | |
| Deborah Kochevar | Elanco Animal Health | 64 | |
| Shiro Kuniya | Takeda Pharmaceutical Co | 63 | |
| Linda Rhodes | Zoetis Inc | 70 | |
| Sanjay Khosla | Zoetis Inc | 68 | |
| Tyler Burns | Canopy Growth Corp | N/A | |
| JeanLuc Butel | Takeda Pharmaceutical Co | 64 | |
| Sarah Kavanagh | Bausch Health Companies | 63 | |
| Andrew Eschenbach | Bausch Health Companies | 78 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | 0.0556 |
Teva Pharma Industries Leadership Team
Elected by the shareholders, the Teva Pharma's board of directors comprises two types of representatives: Teva Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharma's management team and ensure that shareholders' interests are well served. Teva Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nechemia Peres, Independent Director | ||
| Matthew Shields, Executive Operations | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
| Ronit SatchiFainaro, Independent Director | ||
| Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Janet Vergis, Independent Director | ||
| Amir Weiss, Senior Vice President Chief Accounting Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| Richard Francis, CEO President | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Galia Inbar, Executive Vice President - Global Communications, Brand and ESG, Chief Human Resource Officer | ||
| Eli Shani, Executive Vice President - Global Marketing and Portfolio | ||
| Abbas Hussain, Independent Director | ||
| Eric Drape, Executive Vice President - Global Operations | ||
| Vikki Conway, Acting Resources | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Eliyahu Kalif, Chief Financial Officer, Executive Vice President | ||
| Kathleen Veit, Global President | ||
| Ran Meir, Head Relations | ||
| David JD, Executive Officer | ||
| Perry Nisen, Independent Director | ||
| Placid Jover, Executive CHRO | ||
| David Stark, Executive Vice President, Chief Legal Officer | ||
| Tal Zaks, Independent Director | ||
| Kevin Mannix, Head of Global Investor Relations and VP | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Kaare Schultz, President, Chief Executive Officer, Director | ||
| Sol Barer, Independent Chairman of the Board | ||
| Andrew Weil, Chief Accounting Officer | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio and International Markets Commercial | ||
| Dov Bergwerk, Acting Secretary | ||
| Gerald Lieberman, Independent Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Independent Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | 0.0556 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 34.73 B | ||||
| Shares Outstanding | 1.13 B | ||||
| Shares Owned By Institutions | 57.24 % | ||||
| Number Of Shares Shorted | 21.19 M | ||||
| Price To Earning | 15.67 X | ||||
| Price To Book | 3.10 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.85) | Revenue Per Share 14.879 | Quarterly Revenue Growth 0.125 | Return On Assets 0.0556 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.